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Abstract
Background: Light chain amyloidosis (AL) is a rare plasma cell dyscrasia associated with poor
survival especially in the setting of heart failure. Late gadolinium enhancement (LGE) on cardiac MRI
was recently found to correlate with myocardial amyloid deposition but the prognostic role is not
established. The aim is to determine the prognostic significance of LGE in AL by comparing long
term survival of AL patients with and without LGE.
Methods: Twenty nine consecutive patients (14 females; 62 ± 11 years) with biopsy-proven AL
undergoing cardiac MRI with gadolinium as part of AL workup were included. Survival was
prospectively followed 29 months (median) following MRI and compared between those with and
without LGE by Kaplan-Meier and log-rank analyses.
Results: LGE was positive in 23 subjects (79%) and negative in 6 (21%). Left ventricular ejection
fraction was 66 ± 17% in LGE-positive and 69 ± 12% in LGE-negative patients (p = 0.8). Overall 1-
year mortality was 36%. On follow-up, 14/23 LGE-positive and none of LGE-negative patients died
(log rank p = 0.0061). Presenting New York Heart Association heart failure class was also
associated with poor survival (p = 0.0059). Survival between two LGE groups stratified by heart
failure class still showed a significant difference by a stratified log-rank test (p = 0.04).
Conclusion: Late gadolinium enhancement is common and is associated with poor long-term
survival in light chain amyloidosis, even after adjustment for heart failure class presentation. The
prognostic significance of late gadolinium enhancement in this disease may be useful in patient risk-
stratification.
Background
Light chain or primary amyloidosis (AL) is a plasma cell
dyscrasia with production and abnormal deposition of
insoluble fibrillar proteins derived from immunoglobulin
light chains [1,2]. It is a rare disease but can be fatal. Amy-
loid protein deposition in various organs such as the
heart, kidneys, gut and nervous system cause multi-organ
dysfunction. Cardiac involvement was reported in 50% of
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cases [3] and is associated with the worst prognosis;
median survival is about 4 months in the setting of
advanced heart failure [4,5]. Amyloid deposition in the
heart is confirmed by invasive endomyocardial biopsy.
Noninvasive imaging demonstrate that some AL patients
have diffuse subendocardial late gadolinium enhance-
ment (LGE) on cardiac magnetic resonance imaging
(MRI) [6]. Late gadolinium enhancement was found to be
highly correlated to histologic evidence of myocardial
amyloid deposit [7] pointing to its diagnostic potential in
assessing cardiac involvement. Recently, gadolinium
kinetics assessed by intramyocardial (subepicardium and
subendocardium) difference in T1 was found to predict
mortality in AL patients; the presence of LGE showed a
trend, but not significant, of increased mortality [8]. To
further define the prognostic role of LGE in light chain
amyloidosis, the aim of our study is to compare the long-
term survival of AL subjects with and without LGE.
Methods
Patient population and clinical data
Among 36 consecutive patients with biopsy-proven diag-
noses of light chain amyloidosis seen by our Oncology or
Cardiology Division from April 2005–November 2008,
29 underwent cardiac MRI as part of routine workup and
were included in this study. Seven patients did not
undergo cardiac MRI because of low glomerular filtration
rates unsuitable for gadolinium administration and were
not included in this study. The study was approved by the
local Institutional Review Board (IRB). Twenty five
patients signed informed consent as part of a longitudinal
study of light chain amyloidosis and were prospectively
followed. Four patients undergoing workup expired
before recruitment for the study and waiver of consent
was authorized by the IRB for data collection. Their data
were included to ensure 100% capture of consecutively
evaluated AL subjects in our institution. Clinical data was
obtained that included presenting hemodynamic, labora-
tory profile and New York Heart Association heart failure
functional class (I–IV). The latter was adjudicated by a car-
diologist based on presenting symptoms and signs
according to established clinical standards [9]. Low volt-
age on electrocardiogram was defined as ≤ 5 mV in all
limb leads [10]. For analysis, troponin I was dichot-
omized using cutoff values of upper limits of normal in
our institution (0.1 ng/mL) and alkaline phosphatase was
dichotomized using 1.5 times upper limit of normal for
our laboratory following previously published cutoff
thresholds [11]
Cardiac MRI
A General Electric 1.5 Tesla CV scanner was used with 8-
channel cardiac coil. Cardiac gated cine segmented steady
state free precession pulse sequence was performed on
short axis view orthogonal to the long axis of the left ven-
tricle to assess left ventricular function by manual tracing
of endocardial borders using ReportCard software (Gen-
eral Electric, Waukesha WI). The imaging parameters used
were: field of view 34–40 cm, 160 × 256 matrix, 7–8 mm
slice thickness, 2–3 mm gap, flip angle 45°, retrospective
gating. For late gadolinium enhancement imaging, 0.1
mmol/kg of gadolinium (gadodiamide, GE Healthcare or
gadobenate dimeglumine, Bracco Diagnostics) was
injected and imaging started after ~5 minute delay in
short axis and multiple long axis views. Cardiac gated seg-
mented inversion-recovery prepared gradient echo pulse
sequence was used with field of view 38–42 cm, matrix of
256 × 192–256, slice thickness of 7–8 mm, interslice gap
of 2–3 mm, inversion time of 175–300 ms adjusted to
null normal myocardial signal, number of excitations of
1–2 and 2 R-R intervals. The optimal inversion time that
nulls normal myocardium was determined by acquiring
multiple images of the same midventricular view using
different inversion times. If a significant portion of the
myocardium goes through the null point earlier than the
left ventricular cavity blood pool this area was considered
to represent myocardial disease and subsequently the
inversion time was then adjusted to null the remaining
myocardial areas (usually in subepicardial region), an
approach that has been previously validated with histo-
logic gold standard [7]. Two expert readers of cardiac MRI
independently adjudicated the presence or absence of
LGE with agreement of the findings in all cases.
Data and Statistical Analyses
Data are expressed as mean ± standard deviation. Contin-
uous variables were compared between groups using Stu-
dent's t-test (for normal distribution) or Mann-Whitney
rank sum test (for non-normal distribution) using Sigma-
Stat 3.5 software (Systat Software, Inc., Point Richmond
CA). Categorical variables were compared using Fisher's
exact test. Stratified estimates of survival probabilities
were computed using Kaplan-Meier estimators [12] with
log-rank test used to test for group differences in survival
curves. To assess the interaction between heart failure
class and LGE, an exact permutation test based on strati-
fied log-rank test was used to compare the two LGE groups
stratified by heart failure class (MedCalc 9.6.4.0, Mari-
akerke, Belgium, SAS 9.1.3, SAS Institute Cary NC). Cox
multivariable analysis was not performed because of non-
estimable parameters (specifically, the absence of mortal-
ity in the late gadolinium enhancement negative group
does not allow a realistic estimation of the hazard ratio in
Cox regression models) and otherwise unstable parameter
estimates with our small sample size. A p-value less than
0.05 was used to denote statistical significance.BMC Medical Physics 2009, 9:5 http://www.biomedcentral.com/1756-6649/9/5
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Results
Patient population and clinical characteristics
There were 14 females with mean age of 62 ± 11 years.
Biopsy was positive for amyloid in the heart (N = 4, Figure
1), kidneys (N = 14), bone marrow (N = 8), fat pad (N =
5), liver and hip bone (N = 2 each), tongue, gastrointesti-
nal tract and axillary mass (N = 1 each) and all subjects
had abnormal elevation of kappa or lambda light chains
in serum, urine or bone marrow. Thirteen (45%) had
NYHA heart failure class I with 10 (34%), 1 (3%) and 5
(17%) in NYHA heart failure class II, III and IV respec-
tively. The baseline clinical characteristics of the subjects
are described in Table 1. There was no significant differ-
ence in presenting vital signs or laboratory indices
between LGE-positive and LGE-negative patients. There
was a trend which is not significant towards higher pro-
portion of low voltage electrocardiogram in LGE-positive
patients. 91% of LGE-positive and 100% LGE-negative
subjects underwent chemotherapy with or without autol-
ogous stem cell transplantation (Fisher's exact p = 1.0).
Two (out of 23) LGE-positive patients did not have chem-
otherapy: 1 refused chemotherapy and the other had
unstable heart failure.
Cardiac MRI
Late gadolinium enhancement was present in 23 (79%) of
patients (Figure 2). The pattern was subendocardial in all
23 patients with varying degrees of transmurality. The dis-
tribution was found to be global in most cases (Figure 2A–
D) but in some cases was confined to the basal inferola-
teral (Figure 2E–F). Left ventricular ejection fraction was
similar between LGE-positive and LGE-negative groups
(66 ± 17 vs. 69 ± 12%, respectively, p = 0.8) (Table 1). The
inferolateral walls were thicker and left ventricular mass
index were higher in LGE-positive patients.
Clinical Outcomes
Follow-up of survival status was done 26 ± 13 (median
29) months following cardiac MRI. Overall 1-year mortal-
ity was 36% (46% for LGE-positive patients). The imme-
diate cause of mortality was cardiac-related in the majority
of patients (Table 2). Among variables tested by univariate
log-rank analysis, heart failure class and late gadolinium
enhancement were the strongest predictors of mortality
(Table 3). Other variables that were significant included
low voltage on electrocardiogram and inferolateral thick-
ness. Left ventricular ejection fraction was not predictive
of outcome. During the follow up period, 14 of 23 LGE-
positive and 0 of 6 LGE-negative subjects died (log rank p
= 0.0061, Figure 3). Presenting New York Heart Associa-
tion class was a significant univariate predictor of out-
comes (overall log rank p = 0.0059) and patients with
Class I heart failure fared better than Class II–IV (Figure
4). Among those without presenting heart failure (Class
I), 4 of 8 LGE-positive and 0 of 5 LGE-negative patients
died during follow up. Exact log-rank test comparing two
LGE groups stratified by heart failure class still showed a
significant difference (p = 0.04).
Discussion
The study's novel observation is that the presence of late
gadolinium enhancement on cardiac MRI is associated
with poor survival on long-term follow up in light chain
amyloidosis patients and that this MRI finding had inde-
pendent and additive value to clinical assessment of heart
failure status. This may be useful in identifying high risk
Table 1: Clinical characteristics of light chain amyloidosis patients.
LGE+ (N = 23) LGE- (N = 6) p-value
Age (years) 63 ± 12 58 ± 9 0.35
Heart rate (beats per minute) 82 ± 21 71 ± 28 0.26
Systolic blood pressure (mm Hg) 117 ± 18 141 ± 39 0.2
Chemotherapy/Stem cell transplant (N/%) 21 (91) 6 (100) 1.0
NYHA Heart Failure Class (N/%) 0.19
I 8 (35) 5 (83)
II 9 (39) 1 (17)
III 1 (4) 0
IV 5 (22) 0
Laboratory
Low voltage on ECG (N/%) 15 (65) 1 (17) 0.06
Alkaline phosphatase (U/L) 141 ± 151 75 ± 23 0.13
Troponin I (μg/L) 0.51 ± 0.6 0.23 ± 0.3 0.33
MRI
Left ventricular ejection fraction (%) 66 ± 17 69 ± 12 0.8
Anteroseptal thickness (mm) 1.5 ± 0.4 1.12 ± 0.4 0.05
Inferolateral thickness (mm) 1.3 ± 0.4 0.9 ± 0.2 0.0003
Left ventricular mass index (g/m2) 81 ± 30 61 ± 10 0.01BMC Medical Physics 2009, 9:5 http://www.biomedcentral.com/1756-6649/9/5
Page 4 of 7
(page number not for citation purposes)
patients and adds prognostic value to the known diagnos-
tic value of LGE in light chain amyloidosis.
LGE in AL
Light chain amyloidosis is a rare condition but cardiac
involvement is important. Median survival following
standard chemotherapy was reported to be 12–18 months
but with heart failure, the survival is reduced to 4 months
[4,5]. Light chain amyloid heart disease is associated with
significant diastolic dysfunction that results from amyloid
deposition [13,14]. Recently, it was reported that patients
with cardiac amyloidosis demonstrate LGE on cardiac
MRI that correlates closely with biopsy evidence of amy-
loid deposition in the myocardium [6,7]. Although light
chain amyloidosis is a multi-organ disease, prior reports
show that the heart is involved in ~50% of cases [3]. Based
on LGE, our cohort of subjects had a higher proportion of
cardiac involvement, although we lack myocardial biopsy
confirmation in a majority of our subjects (local practice
by our oncologists preclude myocardial biopsy if biopsy
in more accessible organs already establish the diagnosis
in order to reduce patient risk, an approach similar to that
of major amyloid centers [8,15]). The proportion with
LGE is similar to the frequency reported by Maceira and
colleagues (69%) [6]. Our results similarly demonstrate
predominant diffuse subendocardial distribution of LGE,
although some cases were confined to the basal inferola-
teral region.
Late gadolinium enhancement and presenting heart fail-
ure class were the strongest univariate predictors of mor-
tality in our cohort. Heart failure is known to be
associated with poor outcomes in these patients [4,5].
Stratified by heart failure class, LGE remains predictive of
mortality, suggesting additional prognostic value to clini-
cal presentation. Other univariate predictors of mortality
include low voltage on electrocardiogram and inferola-
teral thickness, markers indicative of degree of myocardial
involvement. Light chain amyloidosis is a rare disease and
our single-center study is limited by the small sample size.
Despite the high proportion of mortality in this cohort,
the small sample size and absolute number of mortality
Light chain amyloidosis case Figure 1
Light chain amyloidosis case. A 76 year old with cardiac involvement who had electromechanical dissociation and heart 
failure and expired despite melphalan chemotherapy. A. Cardiac MRI following gadolinium injection demonstrates subendocar-
dial delayed enhancement in the left ventricle and transmural delayed enhancement in the right ventricle. B. Gross specimen 
showing thick left and right ventricles. C and D. Congo red stain without (C) and with polarized light (D) demonstrates diffuse 
interstitial infiltration (arrowhead) and perivascular infiltration (arrow) of amyloid substance.
Cardiac MRI Figure 2
Cardiac MRI. Inversion-recovery prepared segmented gra-
dient echo sequence short axis and long axis images of 3 
patients with late gadolinium enhancement (A-B, C-D and E-
F) and 3 patients without late gadolinium enhancement (G-H, 
I-J and K-L). Note the diffuse left ventricular subendocardial 
enhancement in LGE-positive patients and significant right 
ventricular involvement in the first two subjects. The dark 
nulled normal myocardium is located in the subepicardial 
portion. The dark blood pool signal in LGE-positive subjects 
is consistent with initial observations by Maceira, et al. [6] 
that they related to high myocardial uptake and fast blood 
washout. LV-left ventricle, RV-right ventricle, LA-left atrium, 
RA-right atrium, Ao-aorta, NM-nulled myocardium.BMC Medical Physics 2009, 9:5 http://www.biomedcentral.com/1756-6649/9/5
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Table 2: Causes of mortality
Subject Cause Interval from MRI (months)
1 Multiorgan failure 0.4
2 Renal failure 1.8
3 Sudden cardiac death 2.9
4 Pulmonary and heart failure 18.8
5 Multiorgan failure 1.5
6 Electromechanical dissociation, heart failure 0.5
7 Refractory multiple myeloma 18.3
8 Multiorgan failure 32.8
9 Unknown* 4.4
10 Heart failure 6.3
11 Sudden cardiac death 1.1
12 Pulseless electrical activity 34
13 Heart failure, ventricular tachycardia, pneumonia 1.8
14 Ventricular tachycardia, complete heart block 0.23
*Death was verified from Social Security Death index. Exact cause of death could not be verified.
Table 3: Univariate predictors of mortality.
Variable χ2 p-value
NYHA Heart Failure Class 13.3 0.004
Late gadolinium enhancement 7.5 0.006
Inferolateral thickness > 1.2 cm 5.7 0.02
ECG low voltage 4.4 0.03
Alkaline phosphatase > 104 U/L 3.7 0.06
Left ventricular mass index > 70 g/m2 3.3 0.07
Troponin > 0.1 μg/mL 2.8 0.09
Anteroseptal thickness > 1.2 cm 1.2 0.26
Left ventricular ejection fraction < 60% 0.008 0.93
Late gadolinium enhancement and survival Figure 3
Late gadolinium enhancement and survival. Survival 
plot of light chain amyloid patients with (group 1) and with-
out (group 0) late gadolinium enhancement showing signifi-
cantly reduced survival in LGE-positive patients.BMC Medical Physics 2009, 9:5 http://www.biomedcentral.com/1756-6649/9/5
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preclude Cox multivariable modeling to assess the inde-
pendent interactions among the variables, a significant
limitation of the study. The small sample size leads to
unstable parameter estimates and the absence of mortality
in LGE-negative subjects produces non-estimable hazard
ratios in Cox multivariable techniques. Therefore the
results of the study need to be validated in multicenter
studies involving larger number of patients. Our work rep-
resents a long-term study of the outcomes of light chain
amyloidosis patients following cardiac MRI. The current
study adds strength to the value of LGE in the work up of
light chain amyloidosis: it is useful not only as a diagnos-
tic tool with high sensitivity and specificity for detecting
cardiac involvement as reported by Vogelsberg and col-
leagues [7] but in addition, the presence of LGE has
adverse long-term prognostic implication that may be
useful for risk-stratification. In contrast, Maceira and col-
leagues [8] recently reported that the presence of LGE in
AL subjects had a trend, but not statistically significant, of
reduced survival compared to those without LGE. How-
ever, when they used the T1 difference between subepicar-
dium and subendocardium 2 minutes post-gadolinium
injection, they noted worse prognosis if the difference was
lower than 23 ms. They attributed the difference in prog-
nostic value of gross presence of LGE versus quantification
of gadolinium kinetics in AL by the superior discrimina-
tion by gadolinium kinetics for the severity and transmu-
rality of amyloid burden. Our protocol did not allow us to
measure the intramyocardial T1 difference in our cohort
so this study is not able to confirm their findings.
Potential Mechanism of Adverse Outcomes in AL
The mechanism underlying adverse outcome in patients
with late gadolinium enhancement, a marker of cardiac
amyloid involvement, is not established but may lie in tis-
sue toxicity from light chain amyloid deposition. Autopsy
studies reveal that the presence of amyloid in the perivas-
cular and interstitial space is associated with histologic
evidence of myocardial ischemia in 74% of patients [16].
Epicardial coronary perivascular infiltration is seen in
97% of coronaries that are predominantly but not exclu-
sively non-obstructive [17]; patients present with angina,
have impaired myocardial flow reserve and elevated tro-
ponin, indicating myocyte necrosis [4,18-21]. In colon
specimens, markers of oxidative tissue stress such as lipid
peroxidation products (hydroxynonenal and thiobarbitu-
ric acid reactive substances) and protein carbonyls were
present surrounding amyloid deposits [22]. In rodent
models, brief exposure to light chains derived from light
chain amyloid patients caused oxidative stress leading to
cardiomyocyte dysfunction [23,24]. Amyloid deposition
in the heart is associated with diastolic dysfunction
[10,13,14] but recently, systolic dysfunction in the form
of intraventricular dyssynchrony has been increasingly
recognized [15,25]. Recent data also suggest endothelial
dysfunction in peripheral and coronary arterioles exposed
to AL light chains associated with oxidative stress that may
be contributing to microvascular disease [26,27].
Conclusion
In conclusion, late gadolinium enhancement on cardiac
magnetic resonance imaging is associated with poor long-
term survival in light chain AL amyloidosis, even adjusted
for heart failure class presentation. This finding may be
useful in identifying high risk patients and adds prognos-
tic value to the known diagnostic value of LGE in light
chain amyloidosis.
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